Vildagliptin: the first innovative DDP-4 inhibitor
A review of the main stages of investigation undertaken by Novartis Pharmaceuticals in search of a new molecule for the treatment of type 2 diabetesmellitus, dipeptidyl peptidase-4 (DPP-4) inhibitor (Vildaglyptin). The data on specificity and selectivity of the action of this molecule are presenteda...
Enregistré dans:
Auteur principal: | |
---|---|
Format: | article |
Langue: | EN RU |
Publié: |
Endocrinology Research Centre
2010
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/9ab778ef5d4d43219fab7fe831ded6ca |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|